1. 2352 Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma: Final results of the SUN-CK phase II trial from GERCOR IRC. (September 2015) Authors: Neuzillet, C.; Seitz, J.F.; Fartoux, L.; Malka, D.; Lledo, G.; Tijeras-Raballand, A.; De Gramont, A.; Ronot, M.; Bouattour, M.; Dreyer, C.; Granier, M.; Benner, S.; Amin, A.; Bourget, P.; Hadengue, A.; Roldan, N.; Chibaudel, B.; Raymond, E.; Faivre, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S452 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Impact of circulating biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II study. (December 2016) Authors: Tijeras-Raballand, A.; De Gramont, A.; Chiron, M.; Bachet, J.B.; André, T.; Auby, D.; Desramé, J.; Baba-Ahmed, N.; Lecaille, C.; Lebrun, V.; Louvet, C.; Tournigand, C.; Benner, S.; Attia, M.; De Gramont, A.; Bonnetain, F.; Chibaudel, B. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗